Literature DB >> 14696121

Generation, immunologic characterization and antitumor effects of human monoclonal antibodies for carcinoembryonic antigen.

Takayuki Imakiire1, Motomu Kuroki, Hirotomo Shibaguchi, Hironori Abe, Yasushi Yamauchi, Aruto Ueno, Yumiko Hirose, Hiromi Yamada, Yuichi Yamashita, Takayuki Shirakusa, Isao Ishida, Masahide Kuroki.   

Abstract

We generated fully human mAbs (HmAbs) to carcinoembryonic antigen (CEA) using the KM mouse, which carries a human chromosome 14 fragment containing the entire Ig H chain loci and human kappa L chain segments in the mouse genome. Forty-six hybridoma clones producing HmAbs to CEA were thus obtained by fusing the P3-U1 mouse myeloma cells with splenocytes of the KM mice immunized with CEA. Among them, 22 clones produced HmAbs that reacted with CEA but not with 3 other CEA-related cell adhesion molecule (CEACAM) family members, CEACAM1, CEACAM6 and CEACAM8. In 12 HmAbs examined, 8 were IgG4, 2 were IgG3, 1 was IgG2, and the other was IgG1. The affinity constants for CEA of these HmAbs were comparable to those of the previously prepared mouse anti-CEA mAbs (MmAbs). BIAcore analyses revealed that 1 and 2 of the 22 HmAbs react with 2 epitopes defined by MmAbs on the domain N and the domain A1 or B1 of CEA, respectively. In the presence of human complement in vitro, 2 HmAbs tested showed substantial cytotoxicity, namely, 50-65%, against CEA-expressing tumor cells. With human lymphokine-activated killer cells in vitro, 3 HmAbs tested exhibited 40-65% Ab-dependent cell-mediated cytotoxicity against the tumor cells. Moreover, one of the HmAbs induced a significant inhibition of tumor growth when administered to mice xenografted with the CEA-expressing cells. Considering their lack of immunogenicity to humans, these CEA-specific HmAbs may be useful for immunotherapeutic approaches as well as for immunodiagnosis. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14696121     DOI: 10.1002/ijc.11608

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

1.  A novel anti-CEACAM5 monoclonal antibody, CC4, suppresses colorectal tumor growth and enhances NK cells-mediated tumor immunity.

Authors:  Chaogu Zheng; Jing Feng; Di Lu; Ping Wang; Shu Xing; Jean-Luc Coll; Dongling Yang; Xiyun Yan
Journal:  PLoS One       Date:  2011-06-22       Impact factor: 3.240

2.  Levels of CEACAM6 in Peripheral Blood Are Elevated in Patients with Plasma Cell Disorders: A Potential New Diagnostic Marker and a New Therapeutic Target?

Authors:  N Steiner; R Hajek; D Nachbaur; B Borjan; S Sevcikova; G Göbel; E Gunsilius
Journal:  Dis Markers       Date:  2019-01-27       Impact factor: 3.434

3.  Fully human IgG and IgM antibodies directed against the carcinoembryonic antigen (CEA) Gold 4 epitope and designed for radioimmunotherapy (RIT) of colorectal cancers.

Authors:  Véronique Garambois; Fabienne Glaussel; Elodie Foulquier; Marc Ychou; Martine Pugnière; Robin X Luo; Binyam Bezabeh; André Pèlegrin
Journal:  BMC Cancer       Date:  2004-10-15       Impact factor: 4.430

4.  Triggers of key calcium signals during erythrocyte invasion by Plasmodium falciparum.

Authors:  Xiaohong Gao; Karthigayan Gunalan; Sally Shu Lin Yap; Peter R Preiser
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

5.  Enhancement of antitumor activity by using a fully human gene encoding a single-chain fragmented antibody specific for carcinoembryonic antigen.

Authors:  Hirotomo Shibaguchi; Naixiang Luo; Naoto Shirasu; Motomu Kuroki; Masahide Kuroki
Journal:  Onco Targets Ther       Date:  2017-08-22       Impact factor: 4.147

Review 6.  Human monoclonal antibodies from transgenic mice.

Authors:  N Lonberg
Journal:  Handb Exp Pharmacol       Date:  2008

7.  Highly versatile cancer photoimmunotherapy using photosensitizer-conjugated avidin and biotin-conjugated targeting antibodies.

Authors:  Naoto Shirasu; Hirotomo Shibaguchi; Hiromi Yamada; Masahide Kuroki; Shin'ichiro Yasunaga
Journal:  Cancer Cell Int       Date:  2019-11-15       Impact factor: 5.722

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.